Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.David Andorsky, Jeff P. Sharman, Ralph V. Boccia et al.|Journal of Clinical Oncology|2024Cited by 2
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic MalignanciesKrina K. Patel, Miguel‐Angel Perales, Cameron J. Turtle et al.|Blood|2022Cited by 0